BJE6-106
BJE6-106 (B106) is a potent, selective 3rd generation PKCδ inhibitor with an IC50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC50=50 μM) . BJE6-106 (B106) induces caspase-dependent apoptosis. BJE6-106 (B106) possesses tumor-specific effect.
Product Specifications
CAS Number
[1564249-38-2]
Product Name Alternative
B106
UNSPSC
12352005
Target
Apoptosis; PKC
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bje6-106.html
Purity
99.85
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=CC1=C2C(C=CC(C)(C)O2)=CC(CCN3C4=C(C5=C3C=CC=C5)C=CC=C4)=C1
Molecular Formula
C26H23NO2
Molecular Weight
381.47
References & Citations
[1]Takashima A, et al. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol. 2014 Apr 18;9 (4) :1003-14.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PKCα; PKCδ
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Rhizobium meliloti Beta- (1-->2)glucan export ATP-binding/permease protein NdvA, partial
MAPK13 (Mitogen-Activated Protein Kinase 13, MGC99536, PRKM13, SAPK4, p38delta) (HRP)
